ArticleFrontiers in immunology2026
A scissor-guided single-cell framework defines a macrophage-derived risk score for prognostic and immunotherapy stratification in lung adenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macrophages are key regulators within the lung adenocarcinoma (LUAD) tumor microenvironment, and their functional states and interaction patterns are closely linked to prognosis and immunotherapy response. However, macrophage-associated risk models derived from single-cell features remain limited. Methods: Single-cell datasets from GEO were integrated with TCGA-LUAD transcriptomic profiles to characterize macrophage subpopulations. Scissor was applied to map clinical phenotypes onto single cells and identify phenotype-associated macrophage subsets. Prognostic genes were used to construct a machine learning model termed the Scissor-Associated Macrophage Risk Score (SAMRS), which was evaluated across multiple cohorts. Genomic features, immunotherapy response indicators, cell-cell communication, virtual gene knockout, spatial transcriptomics, and functional experiments were further incorporated for mechanistic validation. Results: Multiple functionally distinct macrophage subsets were identified, and Scissor+ macrophages were associated with poor prognosis and oncogenic pathway activity. Communication analysis placed macrophages at central signaling positions. The SAMRS model achieved robust prognostic stratification across cohorts. High SAMRS scores were linked to higher mutation burden but stronger immune evasion signals, whereas low SAMRS scores showed more favorable predicted immunotherapy response. The model gene TIMP1 demonstrated consistent signals across bulk, single-cell, and spatial analyses, and functional experiments supported its tumor-promoting role. Conclusion: A single-cell phenotype-guided macrophage risk score, SAMRS, was developed for prognostic stratification and immunotherapy response assessment in LUAD. TIMP1-related regulatory programs may contribute to macrophage-associated tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.